211 related articles for article (PubMed ID: 32761818)
41. Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Green J; Carroll W; Gilchrist FJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012798. PubMed ID: 30075058
[TBL] [Abstract][Full Text] [Related]
42. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
43. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
44. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
Johannessen M; Andreasen RB; Nordfang O
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803
[TBL] [Abstract][Full Text] [Related]
45. Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.
Martí-Carvajal AJ; Conterno LO
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD005598. PubMed ID: 27841444
[TBL] [Abstract][Full Text] [Related]
46. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
47. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.
Franchini M; Mannucci PM
Br J Clin Pharmacol; 2011 Oct; 72(4):553-62. PubMed ID: 21204915
[TBL] [Abstract][Full Text] [Related]
48. Interventions for treating intrahepatic cholestasis in people with sickle cell disease.
Martí-Carvajal AJ; Martí-Amarista CE
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD010985. PubMed ID: 28759700
[TBL] [Abstract][Full Text] [Related]
49. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
50. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2015 Nov; (11):CD010288. PubMed ID: 26545165
[TBL] [Abstract][Full Text] [Related]
51. Treatment of dental and orthodontic complications in thalassaemia.
Mulimani P; Abas AB; Karanth L; Colombatti R; Kulkarni P
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012969. PubMed ID: 31425614
[TBL] [Abstract][Full Text] [Related]
52. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2013 Sep; (9):CD010288. PubMed ID: 24043500
[TBL] [Abstract][Full Text] [Related]
53. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Bhatt J; Jahnke N; Smyth AR
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD002009. PubMed ID: 31483853
[TBL] [Abstract][Full Text] [Related]
54. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.
Marshall M; Crowther R; Almaraz-Serrano A; Creed F; Sledge W; Kluiter H; Roberts C; Hill E; Wiersma D; Bond GR; Huxley P; Tyrer P
Health Technol Assess; 2001; 5(21):1-75. PubMed ID: 11532238
[TBL] [Abstract][Full Text] [Related]
55. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive care for hemophilia and other inherited bleeding disorders.
Page D
Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
[TBL] [Abstract][Full Text] [Related]
57. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.
Regan KH; Bhatt J
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD009876. PubMed ID: 30997925
[TBL] [Abstract][Full Text] [Related]
58. Blood transfusions for treating acute chest syndrome in people with sickle cell disease.
Dastgiri S; Dolatkhah R
Cochrane Database Syst Rev; 2016 Aug; (8):CD007843. PubMed ID: 27574910
[TBL] [Abstract][Full Text] [Related]
59. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
60. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
